Stock comparison
Cytek Biosciences
LeMaitre Vascular
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
CTKB
Cytek Biosciences
Market cap
$517.86M
Sector
Healthcare
LMAT
LeMaitre Vascular
Market cap
$2.23B
Sector
Healthcare
Overall winner
LeMaitre Vascular LMAT
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | CTKB | LMAT | Winner |
|---|---|---|---|
| Warren Buffett | 21F | 77B | LMAT |
| Benjamin Graham | 35D | 89A | LMAT |
| Philip Fisher | 30F | 81C | LMAT |
| Peter Lynch | 22F | 67B | LMAT |
| Joel Greenblatt | 0F | 56D | LMAT |
| Charlie Munger | 21F | 68D | LMAT |
| Terry Smith | 23F | 69D | LMAT |
Side-by-side metrics
| Metric | CTKB | LMAT |
|---|---|---|
| Market cap | $517.86M | $2.23B |
| P/E (TTM) | - | 37.1x |
| EV/EBIT | - | 36.6x |
| ROIC (TTM) | -11.42% | 9.43% |
| Gross margin | 51.7% | 72.39% |
| Net margin | -36.25% | 24.35% |
| Revenue CAGR 5y | 12.02% | 12.75% |
| EPS CAGR 5y | - | 19.04% |
| Debt / Equity | 0.1x | 0.5x |
| Dividend yield | 0.0% | 0.84% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
CTKB leads on
- EV/EBIT-vs 36.6x+133%
- P/E (TTM)-vs 37.1x+119%
- Debt / Equity0.1xvs 0.5x+76%
LMAT leads on
- ROIC (TTM)9.43%vs -11.42%+183%
- Net margin24.35%vs -36.25%+167%
- Dividend yield0.84%vs 0.0%+100%
- Market cap$2.23Bvs $517.86M+77%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.